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Objective: Generate DNA aptamers to inhibit IL-17RA-mediated synovial inﬂammation in an experimental
mouse model of osteoarthritis (OA).
Methods: A novel cell-SELEX method was applied to obtain DNA aptamers speciﬁc for IL-17RA. A single-
stranded (ss) DNA library with four30 probes was synthesised. By incubating this library with NIH3T3
cells, we collected DNA ligands that could bind the cell surface. The collected ligands were incubated
with IL-17RA-deﬁcient NIH3T3 cells, and unbound ssDNA was harvested from the supernatant for the
next round of selection. After 12 cycles, speciﬁc aptamers against IL-17RA were generated. For animal
experiments, a meniscectomy was performed on Balb/C mice to generate an animal model of OA. Mice
received weekly intra-articular (i.a.) injections of aptamers or control treatments for 6 weeks. Synovial
membranes were evaluated by histomorphology and the mRNAs of critical inﬂammatory cytokines were
measured by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR).
Results: An aptamer termed RA10-6 was obtained that could efﬁciently block IL-17 binding to IL-17RA in
a dose-dependent manner in vitro. Histological examination and quantitative RT-PCR results showed that
OA mice that injected with RA10-6, especially in combination with celecoxib demonstrated inhibition of
synovial thickening and reduction in IL-6 levels in the synovial tissue.
Conclusion: Our results suggest that RA10-6 can inhibit synovial inﬂammation by blocking IL-17/IL-17RA-
mediated IL-6 expression. RA10-6 acted synergistically with celecoxib to inhibit IL-6 expression in
synovial tissues. Thus, aptamers targeting IL-17RA might serve as potent adjunctive agents for the early
treatment of OA.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is an articular disease characterised by
synovium inﬂammation and progressive cartilage degradation that
leads to chronic pain and functional restrictions in affected joints.
The IL-17 family of cytokines and one of its receptors, IL-17RA, have
been reported to be closely associated with OA pathogenesis1e5. IL-
17RA, also known as IL-17R, is a type I transmembrane glycoproteinDongqing Li, Department of
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s Research Society International. Pwith a molecular mass of 120 kDa. This receptor has a broad tissue
distribution and plays a central role in inﬂammatory responses. IL-
17/IL-17RA-mediated signal transduction is required for the
expression of inﬂammatory cytokines including IL-1, IL-6 and IL-8,
which contribute to inﬂammation6,7.
Presently, many studies have shown that IL-17 responsiveness
could be suppressed by the use of speciﬁc siRNAs or mAbs against
IL-17RA. The agents that target IL-17RA seem to have tremendous
potential as OA or rheumatoid arthritis (RA) therapies. In this study,
we applied a cell-SELEX-basedmethod (cell systematic evolution of
ligands by exponential enrichment)8,9 to isolate high-afﬁnity DNA
ligands (termed aptamers) for IL-17RA. Aptamers have several
potential advantages over antibodies and siRNA. Aptamers, small
sized DNA ligands rather than protein or RNA, are easily cleared
from the blood. They can be easily chemically-modiﬁed and are
non-immunogenic. In addition, they are readily synthesised and do
not cause side effects resulting from unwanted immune responses
in hosts10.ublished by Elsevier Ltd. All rights reserved.
Fig. 1. The procedure of cell-SELEX based on NIH3T3 cells and IL-17RA-deﬁcient
NIH3T3 cells.
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that differed only in IL-17RA expression. We ﬁnally generated an
aptamer named RA10-6 that efﬁciently blocked IL-17 binding to IL-
17RA in vitro and also inhibited synovium thickening by reducing
IL-6 production in a murine model of experimental OA.
Materials and methods
Construction of IL-17RA-shRNA expression vectors
The pSilencer2.1-U6 shRNA expression vector used in this study
was purchased from Ambion Inc., USA. A 21-nucleotide (nt) target
sequence located between nucleotides 1623 and 1641 of the mouse
IL-17RA gene (GenBank accession number: NM_008359)11 was
selected and the two following oligonucleotides were synthesised:
IL-17RA (top) 50-GATCGGCACCTACGTTGTTTGCTATTCAAGAGA
TAGCAGACT-ACGTAGGTGCTTTTTTGGAAA-30; IL-17RA (bottom)
50-AGCTTTTCCAAAAAAGCACCTACGTAGTCTGCTATCTCTTGA-ATAG
CAGACTACGTAGGTGCG-30. Oligonucleotides were annealed and
inserted into pSilencer2.1-U6 as previously described12 to produce
a recombination plasmid.
Stable transfection
NIH3T3 cells were grown in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) medium (Gibico, USA) supplemented with 10%
foetal bovine serum (FBS). A total of 4.5105 cells were transfected
with 4 mg of plasmid using Lipofectin2000 (Invitrogen, USA). Stably
transfected cells were generated by culturing transfected cells with
0.5 mg/ml G418 (SigmaeAldrich, USA) supplemented medium.
Single-stranded (ss) DNA library
The library was designed and oligonucleotides templates were
synthesised as a single stranded 88-mer with the following
sequence: 50-GCGGAATTCTAATACGACTCACTATAGGGAACAGTCCGA
GCC-N30-GGGTCAATGCGTCATA-30, where the central N30 repre-
sents random oligonucleotides based on equal incorporation of A,
G, C and T at each position as previously reported13. The comple-
mentary strand was synthesised using a DNA polymerase I Klenow
fragment with primer1: 50-GCGGGATCCTATGACGCATTGACCC-30,
where the underlined oligonucleotides contained a BamHI site. The
double-stranded (ds) DNA molecules were generated by PCR
ampliﬁcation using primer1 and primer2: 50-GCGGAATTCTAA
TACGACTCACTATAGGGAACAGT-30, where the underlined oligonu-
cleotides contained an EcoR I site.
Generating the aptamer by cell-SELEX
As shown in Fig.1, the ssDNA library was pretreated sequentially
by being heated at 90C for 5 min, snap-cooled on ice for 2 min and
incubated in binding buffer [25 mM TriseHCl, 50 mM KCl, 200 mM
NaCl, 0.2 mM ethylenediamine tetraacetic acid (EDTA), 5% (v/v)
glycerol, and 0.5 mM dithiothreitol (DTT)] for 30 min at 37C. The
treated library was incubated with 106 NIH3T3 cells, followed by
washes with at least 40 column volumes of binding buffer. Samples
were then centrifuged to remove unbound ssDNA from superna-
tant. The bound ssDNA was used as the template for PCR to obtain
the ssDNA pool for the next round of selection. To obtain aptamers
with a high-binding efﬁciency to NIH3T3 cells, the selective pres-
sure was progressively increased by increasing the number of
washes and decreasing the incubation time. Following NIH3T3 cell
selection in each cycle, a counter-selection step was performed to
obtain aptamers speciﬁc to IL-17RA. The ssDNA pool from the
previous round was incubated with IL-17RA-deﬁcient NIH3T3 cellsand then centrifuged as described above. Afterwards, the precipi-
tate was discarded (because ssDNA that binds to IL-17RA-deﬁcient
NIH3T3 cells is not speciﬁc for IL-17RA) and the supernatant was
harvested as the PCR template for the next step. After 12 rounds of
selection, the afﬁnity of aptamer pools was analyzed by ﬂow
cytometry and the samples with the highest afﬁnity were cloned
into pUC19 and sequenced. To identify the minimal sequence
elements that conferred high afﬁnity binding to the target, the
secondary structures of the single aptamers were predicted using
DNAMAN6.0 software.Animals and operative procedure
Eight-week-old intact female Balb/C mice were purchased from
the Animal Centre of Wuhan University. The mice were anaes-
thetised and knee joint instability was induced surgically by
a medial meniscectomy performed using microscopic lenses14. The
right knee was opened and the meniscotibial ligament was
sectioned to access the medial meniscus. After being freed, the
medial meniscus was removed using surgical forceps and sectioned
using an ophthalmologic scalpel. Muscles and skin were stitched
closed to restore muscle integrity. The left knees of these mice
underwent a sham operation (a single cutaneous incision) and
were then stitched closed. The day after surgery, mice were divided
into ﬁve groups, with six animals per group. These groups received
either intra-articular injections (i.a.) of phosphate buffered saline
(PBS) with 2 mg anti-IL-17 polyclonal antibody or aptamers at
concentrations of 2 mg, 4 mg or 8 mg in equal volumes. The injections
were administered once a week for 6 weeks. For the celecoxib anti-
inﬂammation experiment, mice either received 200 U celecoxib by
intragastrical injection alone or were injected i.a. with 4 mg or 8 mg
aptamers in combination. Six weeks after surgery, mice were
sacriﬁced and the knee joints were resected for haematox-
ylineeosin staining and the synovial tissues were obtained for
quantitative reverse transcriptase-polymerase chain reaction (RT-
PCR) and gel electrophoresis. All experiments complied with the
guidelines for animal experimentation issued by the local Ethics
Committee on Animal Care and Experimentation.
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A 6-week toxicological study was performed on Balb/C mice to
assess the safety of RA10-6. The four treatment groups each con-
sisted of six females. Mice were anaesthetised and six weekly
injections into the knee articular cavity were administered. Group 1
received 10 ml PBS as a control, while Groups 2, 3 and 4 received
2 mg, 4 mg and 8 mg RA10-6 dissolved in 10 ml PBS, respectively.
Animals were evaluated daily for changes in clinical signs, appetite
and body weight. Six weeks after the ﬁrst administration, mice
were sacriﬁced and the spleen weight/body weight (S/B weight)
ratio was calculated.
The lymphocyte transformation test was performed to prelim-
inarily evaluate the immune response in RA10-6 treated mice.
Brieﬂy, B cells, CD4þ T cells and CD8þ T cells were puriﬁed from
splenocytes using BD Imagmouse B lymphocyte, CD4þ T or CD8þ
T lymphocyte enrichment sets (DM, BD Biosciences) in a negative
selection procedure. Puriﬁed lymphocytes at a density of 2104
cells per well in 96-well plates were stimulated with 5 mg/ml
lipopolysaccharide (LPS) (for B cells) or concanavalin A (ConA) (for
T cells) for 72 h. A total of 1 mCi [3H] thymidine was added to each
well and mixtures were incubated for 20 h. Cells were collected on
glass ﬁbre ﬁller mats and dried at 80C. [3H] Thymidine incorpo-
ration, in cpm, was measured in a liquid scintillation counter. The
results are expressed as stimulation index (SI), where SI¼ (mean
cpm of stimulated)/(mean cpm of non-stimulated).
Real-time quantitative RT-PCR assay
To identify the stable transfected NIH3T3 cells, total RNA was
extracted from cells using the Quick Prep total RNA extraction kit
(Pharmacia Biotech, Hillered, Denmark), reverse transcribed using
oligo (dT)12e18 and Superscript II reverse transcriptase (Life
Technologies Inc., Grand Island, NY). To analyze gene expression of
synovial tissues in experimental OA mice, synovial tissues from
micewere crushed and homogenized. Total RNAwas then extracted
and processed for RT-PCR. The real-time quantitative PCR was
performed in a Rotor-Gene3000 Systems instrument using the
SYBR Green PCR Handbook kit (QIAGEN, Germany). The primer
sequences were as follows:
b-actin forward, 50-GACAACGGCTCCGGCATGTGCAAG-30;
reverse, 50-ATGCCCACCATCACGCCCT-30;
IL-17RA forward, 50-ACCTGCCTGGATGACAGCT-3; reverse,
50-CGTCTGTCTGCAGTGTCCATTC-30;
IL-1b forward, 50-TGCTGTCCAGACGAGGGCAT-30; reverse,
50-ACTCTCCAGCTGCAGGGTAG-30;
IL-6 forward, 50-AGACCTGTCTATACCACTTC-30; reverse,
50-CACGTTACCGTTAAGACTAA-3;
IL-8 forward, 50-CCACGCTCAAGTCCCTCAA-30; reverse,
50-ACGGTCTTGCCCCACTTAC-30.
All cDNAs were diluted to contain equal amounts of b-actin. PCR
conditions were 3 min at 94C followed by 40 cycles with 30 sec at
94C, 30 sec at 57C and 30 sec at 72C in each cycle. The results
were analyzed by Rotor-Gene Real-Time Analysis Software v6.0.41.
Flow cytometry
For assessment of surface IL-17RA expression, NIH3T3 cells or
IL-17RA-shRNA stably transfected NIH3T3 cells were harvested and
suspended in PBS incubated with 5 mg/ml of PE-labelled-anti-IL-
17R for 20 min. The stained cells were then analyzed in a Beckman
Coulter EPICS ALTRA II ﬂow cytometer. PE-labelled anti-mouse
IgG2awas used as a negative control. To demonstrate the afﬁnity of
aptamers, ﬂuorescein isothiocyanate (FITC)-labelled aptamerswere
isolated from pUC19-aptamer recombination plasmids using PCRwith FITC-labelled primers (primer1 and primer2). FITC-labelled
aptamers (8 mg) were incubated with 4105 NIH3T3 cells or IL-
17RA-shRNA stably transfected NIH3T3 cells at 37C for 15 min.
Subsequently, samples were centrifuged at 1000 rpm for 5 min and
the supernatant was discarded. Cells were washed with PBS and
analyzed by ﬂow cytometry. The binding afﬁnity was calculated by
the following formula15: Kd¼ (Bmax X/Y) X, where Bmax was the
maximum percentage of ﬂuorescence, Y was the mean percentage
ﬂuorescence and X was the molar concentration.
Enzyme-linked immunosorbent assay (ELISA)
To identify IL-17RA as the target of selected single aptamers,
2 mg/ml of mouse recombinant IL-17R protein was coated onto
plates for a solid phase binding experiment. Plates were incubated
with IL-17R at 4C overnight and blocked with 1% bovine serum
albumin (BSA). These plates were washed with PBS and each well
was treated with 100 ml of 4 mg/ml biotin-labelled aptamers (syn-
thesised by SBS Company, Shanghai, China). Wells were incubated
for 1 h at 37C and washed again. Subsequently, the samples were
incubated with 100 ml horseradish peroxidase (HRP)-streptavidin
at a dilution of 1:1000 at 37C for 30 min. Finally, the samples were
developed with a substrate solution containing o-phenylenedi-
amine and absorbance of each sample was measured at 450 nm.
To analyze whether RA10-6 can block IL-17 combined with
IL-17RA, we performed a sandwich ELISA. Brieﬂy, 96-well ELISA
plates were pre-coated with 2 mg/ml of IL-17R protein overnight at
4C. After incubation with RA10-6 (ranging from 0 mg to 32 mg) at
room temperature for 1 h, the plates were washed and combined
with recombinant mouse IL-17A protein for 30min. IL-17A protein
bindingon theplatewasdetectedbymouse IL-17 biotinylated afﬁnity
puriﬁed Ab and developed by HRP-streptavidin and its substrate
solution. Absorbances of these samples were measured at 450 nm.
All antibody and protein used in ELISA and ﬂow cytometry were
purchased from R&D Systems Inc., USA. Each sample was repeated
in triplicate and each experiment was repeated three times.
Statistical analysis
All data (excluding morphology data) are expressed as the 95%
conﬁdence interval (CI) of mean. Flow cytometry, ELISA and gene
expression assay data were analyzed by one-way analysis of vari-
ance (ANOVA) analysis. P-values less than 0.05 were considered
signiﬁcant.
Results
IL-17RA-deﬁcient NIH3T3 cells model
IL-17RA mRNA level and cell surface IL-17RA expression were
examined by quantitative RT-PCR and ﬂow cytometry. The IL-17RA
mRNA concentration in IL-17RA-shRNA stably transfected NIH3T3
cells and non-transfected NIH3T3 cells were 0.21e0.34 ng/ml and
0.77e1.31 ng/ml, respectively (95% CI of mean, n¼ 3). In addition,
IL-17RA mRNA in IL-17RA-shRNA stably transfected cells exhibited
a higher mean Ct value (21.51) during ampliﬁcation, whereas non-
transfected cells exhibited a lower Ct value (17.36). Generally, the
more unique the DNA template is, the fewer threshold cycles are
required for detection. Flow cytometry assays showed that non-
transfected NIH3T3 cells expressed IL-17RA moderately (95% CI of
mean, 46e78%, n¼ 3), whereas IL-17RA-shRNA stably transfected
cells rarely expressed IL-17RA (95% CI of mean, 12e29%, n¼ 3).
These results suggest that NIH3T3 cells stably transfected with
IL-17RA-shRNA vectors have a low level of IL-17RA expression.
Table I
Binding ability of selected aptamers from cell-SELEX
Binding percentage (%) (95% CI of mean, n¼ 3) OD 450 nm (95% CI of mean, n¼ 3)
NIH3T3 IL-17RA-deﬁcient
NIH3T3
Biotin-aptamer combined
with IL-17R
Aptamer blocker IL-17 combined
with IL-17R
RA10-6 RA10-2
Aptamer pools Blank 1.5e2.0 1.7e2.3 PBS 0.06e0.24 0 mg 0.16e0.82 0.40e0.62
Seventh 15.0e35.6 12.4e29.6 Anti-IL-17R 0.81e1.01 2 mg 0.16e0.56 0.23e0.68
Eighth 24.0e42.0 11.8e26.6 R10-6y 0.30e0.99 4 mg 0.16e0.34 0.32e0.60
Ninth 29.0e71.2 4.3e19.9 R10-2 0.08e0.34 8 mg 0.10e0.44 0.37e0.44
Tenth 46.8e89.2 3.7e8.1 R10-7 0.06e0.50 16 mg 0.02e0.36 0.25e0.48
Eleventh 35.8e59.8 0.3e8.3 R10-13 0.26e0.36 32 mg 0.08e0.22 0.27e0.45
Twelfth 43.4e53.8 3.4e6.6 R10-14 0.13e0.41
Single aptamer from
the tenth pool
Blank 0.3e3.3 1.6e3.4
RA10-2 15.8e31.0 0.4e12.1
RA10-6* 56.6e79.4 0.4e13.3
RA10-7 26.0e73.9 6.4e15.6
RA10-13 8.1e57.8 5.6e14.4
RA10-14 31.6e66.4 6.3e8.9
Comparisons considered signiﬁcant when P< 0.05. “Blank” means cells were cultured without aptamer.
* P¼ 0.001 vs Blank, RA10-2 and RA10-13; P¼ 0.009 vs RA10-7; P¼ 0.006 vs RA10-14.
y P¼ 0.001 vs RA10-2, RA10-7, RA10-13 and RA10-14.
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described as an IL-17RA-deﬁcient cell line.
Aptamers with high afﬁnity for IL-17RA isolated by cell-SELEX
After 12 rounds of selection, aptamers pooled from each round
were obtained. Flow cytometry results showed that the tenth pool
had the highest binding percentage for NIH3T3 cells (Table I). The
Kd value of aptamer pools was calculated based on the ﬂow
cytometry results. This analysis showed that the tenth pool had
a lower Kd value than other pools (Table II). These results demon-
strated that the tenth pool had a high afﬁnity for IL-17RA. There-
fore, aptamers from the tenth pool were cloned into pUC19 and 20
individual clones were selected and sequenced. Among these
sequences, the single aptamer RA10-6 dominated the selection
process and constituted 25% of the population. The remaining
single aptamers appeared only once (Table III). The results of the
secondary structure analysis showed that the consensus sequences
CTAG and/or its reverse sequence GATC were present in the
nucleotides of the N30 sequence (present nine times among the 20
clones). Both the CTAG and GATC sequences were located in the
terminal loop of the secondary structure. We found RA10-6
possessed two stem-loop structures and a CTAG or GATC sequence
was located in each one of them. The other selected single aptamers
were single-stem-loop structures with a CTAG or GATC sequence in
their terminal loops (Table III).
Aptamer RA10-6 binding to IL-17RA in a dose dependent manner
FITC-labelled single aptamers were incubated with cells and
analyzed by ﬂow cytometry. As shown in Table I, there were no
statistically signiﬁcant differences in single aptamers binding toTable II
Binding afﬁnity (Kd value) of aptamer
Aptamer pools Kd (nM) Single aptamers
from tenth pool
Kd (nM)
Seventh 49.1 8.4 RA10-2 5.9 1.4
Eighth 25.6 3.8 RA10-6 1.2 0.4
Ninth 18.7 0.9 RA10-7 4.3 0.9
Tenth 2.1 0.9 RA10-13 3.8 1.9
Eleventh 18.6 3.1 RA10-14 4.0 0.6
Twelfth 33.3 7.0IL-17RA-deﬁcient NIH3T3 cells. However, the percentage (95% CI
of mean, n¼ 3) of NIH3T3 cells bound with RA10-6 was
56.6e79.4%, which was much higher than other single aptamers
(RA10-2: 15.8e31.0%; RA10-7: 26.0e73.9%; RA10-13: 8.1e57.8%;
RA10-14: 31.6e66.4%). The differences of RA10-6 vs other
aptamer treated groups were signiﬁcantly different (*P¼ 0.001 vs
RA10-2 and RA10-13; *P¼ 0.009 vs RA10-7; *P¼ 0.006 vs RA10-
14). For ELISA analysis, biotin-aptamers were combined with pre-
coated IL-17RA protein and detected by HRP-streptavidin and
o-phenylenediamine. The optical density (OD) 450 nm value
showed that the efﬁciency of RA10-6 binding to IL-17RA protein
was less than anti-IL-17R (*P¼ 0.046 vs anti-IL-17R) but higher
than other selected single aptamers (*P¼ 0.001 vs RA10-2, RA10-
13 and RA10-14) (Table I). In addition, the RA10-6 aptamer
blocked IL-17 binding to IL-17RA protein in a dose dependent
manner (Table I). These results indicate that aptamer RA10-6 can
speciﬁcally bind to puriﬁed IL-17RA protein or IL-17RA expressed
on the surface of NIH3T3 cells and did not bind to IL-17RA-
deﬁcient NIH3T3 cells.
RA10-6, especially combined with celecoxib prevented synovium
tissue thickening in an OA mouse model
Loeuille et al. reported that synovial thickening was observed in
73% of joints with early OA16. In present study, it was found that OA
mice injected i.a. with RA10-6 exhibited microscopic features of
thinner synovial membranes than mice that were injected with
PBS. The repression effect of combined action of celecoxib and
RA10-6 on synovium thickening is stronger than celecoxib alone
(Fig. 2).
RA10-6 inhibited IL-6 expression of synovial tissues in a dose
dependent manner
IL-17A can stimulate synoviocytes to produce more IL-1b, IL-6
and IL-8, which are key inﬂammatory mediators involved in OA
pathogenesis6,17. To demonstrate whether IL-17A/IL-17RA-medi-
ated cell responsiveness is affected by RA10-6, the mRNA of critical
cytokines from mouse synovial tissues was detected by real-time
quantitative RT-PCR. Compared with PBS controls, RA10-6 could
not inhibit the expression of IL-1b and IL-8 (Table IV); however, IL-6
mRNA levels were reduced by injection of RA10-6 in a dose
Table III
Single aptamers isolated from the tenth pool
Aptamer Sequences (N30) 50e30 Frequency
RA10-2 1/20
RA10-6 5/20
RA10-7 1/20
RA10-13 1/20
RA10-14 1/20
Consensus GATC and/or CTAG
Predicted secondary structure of N30 in aptamers
Consensus regions within the individual aptamers are labelled with a red box or red point.
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by approximately 1.5-fold at 4 mg (*P¼ 0.002 vs PBS control) and
by approximately two-fold at 8 mg (*P¼ 0.0001 vs PBS control)
(Table IV).Celecoxib synergised with RA10-6 to decrease IL-6 more than
celecoxib or RA10-6 alone
Celecoxib, a speciﬁc COX-2 inhibitor, is a widely used drug in
clinical therapy of OA. It was reported that celecoxib could down-
regulate IL-6 levels in synovial cells and, consequently, relieve
inﬂammation18e20. As is shown in Table IV, RA10-6-mediated IL-6
inhibition was inferior to celecoxib, but the combined action of
celecoxib and RA10-6 (both at 4 mg and 8 mg) reduced the
percentage of IL-6 expression compared to celecoxib alone. No
signiﬁcant difference between 4 mg and 8 mg RA10-6 was found
when combined with celecoxib (P¼ 0.454), indicating that the
effect of two concentrations of RA10-6 on amplifying celecoxib
effect is almost the same.RA10-6 did not induce systemic effects or immunotoxic effects in
mice
No animals died during the course of the study and no signiﬁ-
cant clinical signs or changes in body weight were observed. In
addition, the food consumption changes for all groups were within
the expected range. These changes most likely result from the
systemic narcotic effects. No RA10-6 related skin necrosis around
the knee was detected by ordinary observation. For analyses of
RA10-6 related immunotoxic effects, mouse S/B weights were
calculated when animals were killed after the six weekly i.a.
injections. Additionally, proliferation responses to LPS or ConA in
vitrowere measured in B cells, CD4þ and CD8þ T cells isolated from
the spleen. As is shown in Table V, no signiﬁcant difference con-
cerning S/B weight or lymphocyte proliferation was observed
among the groups. These data indicated that RA10-6 at a weekly
dose of no more than 8 mg did not produce any signiﬁcant effect in
the mouse immune system.Discussion
OA is the most common joint disorder worldwide and previous
studies have indicated that cytokines such as IL-17 can directly acti-
vate or synergise with IL-1b or TNF-a to amplify and accelerate
articular damage21e26. Presently, most researches addressing anti-
cytokine therapy forOAhavebeen focusedon IL-1bor TNF-ablockade
(such as IL-1R antagonist protein and anti-TNF)27,28. However, little
attention has been given to developing inhibitors of IL-17RA-medi-
ated responsiveness during synovial inﬂammation. Chabaud et al.
demonstrated that soluble IL-17R (sIL-17R) or anti-IL-17 can inhibit
the production of other pro-inﬂammatory and/or anabolic cytokines
that may be helpful in the repair of articular cartilage29,30. However,
these agents are limited for general therapeutic applications because
of their high cost. Hence, we aimed to obtain novel blocking agents
that targeted IL-17RA in an effort to block IL-17/IL-17RA-mediated
synovial inﬂammation in a murine model of OA.
Cell-SELEX is a powerful method to obtain aptamers as potent
therapeutic agents for disease treatment. Currently, most aptamer
research has focused on cancer diagnosis and therapy, diabetic reti-
nopathy, renalﬁbrosis andpathogen infection13,31,32. This is especially
true for AS1411,which is an aptamer targeting the cell surface protein
nucleolin and is being administered systemically in clinical trials.
However, the usage of aptamers in OA has not beenwell reported. In
this work, we utilized IL-17RA-deﬁcient NIH3T3 cells as a reverse
selection target to eliminate non-speciﬁc aptamers. By using
a modiﬁed cell-SELEX method, we generated an IL-17RA blocking
agent (RA10-6) for the ﬁrst time. Our data showed that the sequence
of RA10-6 appearedmost frequently among the ﬁnal obtained clones
(ﬁve of 20 targets). Furthermore, RA10-6 was identiﬁed to be a high
afﬁnity ligand forNIH3T3 cells and IL-17Rprotein invitro compared to
other aptamers. In addition, we also conﬁrmed that RA10-6 could
block IL-17 binding to IL-17R protein in a dose dependent manner.
To determine if RA10-6 inhibited IL-17/IL-17R-mediated
inﬂammatory reactions in vivo, an OA mouse model was employed.
Animals were injected i.a. with RA10-6 once a week. We observed
that RA10-6 treatment, especially in combination with celecoxib,
inhibited synovial thickening and decreased IL-6 levels in the
synovial tissue of mice. Synovial thickening is one of the charac-
teristics of synovial inﬂammation and is observed in 73% of joints
Fig. 2. Microscopic features of the thickness of synovial tissues. Mice injected i.a. with 4 mg RA10-6 (upper right) displayed much thinner synovium than those injected with
equal volume of PBS (upper left). The repression effect of combined action of celecoxib and RA10-6 (middle right) on synovium thickening is stronger than celecoxib alone (middle
left). Section from Sham-operated mouse (bottom) showed the normal structure of synovial tissues. T¼ tibia; F¼ femur; S¼ synovium; M¼Meniscus; CELE¼ celecoxib. The
hyperplasia of synovium in articular cavity was marked in black arrows. Small maps (Magniﬁcation 200) within each larger picture (Magniﬁcation 100) are arrow pointed areas.
Fig. 3. Quantitative RT-PCR products of IL-6 were identiﬁed by agarose gel electro-
phoresis. Corresponding data were shown in Table IV.
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that promotes exacerbation of synovial inﬂammatory inﬁltration
and cartilage erosion in the early stages of OA. IL-6 is predominantly
secreted by synovial ﬁbroblasts when these cells are activated by IL-
17A, IL-17F, IL-21 and IL-2211,33. We hypothesize that RA10-6 can
occupy the binding site of IL-17RA on the surface of synovial cells
because IL-17A and IL-17F did not activate their receptors and did
not induce downstream gene expression. However, IL-6 may not be
the only cytokine that is changed after aptamer treatment. This
concern is a limitation of our present study; hence, the decrease of
synovial thickening observed with aptamer treatment may be due
to a decrease in IL-6 levels. Some studies have reported that IL-17
was able to induce the release of IL-1b, IL-6 and IL-8 in synovio-
cytes34. Accordingly, we observed that the polyclonal anti-IL17
Table IV
Cytokine mRNA expression 6 weeks after receiving six weekly i.a. injections with
RA10-6 or receiving celecoxib by intragastrical
Concentrations (ng/ml) (95% CI of mean, n¼ 6)
Group IL-1b IL-6 IL-8 Group IL-6
Sham 2.7e11.2 2.2e6.8 2.4e4.2 Sham 8.0e14.2
PBS 14.5e40.3 28.2e39.6 8.0e11.6 PBS 23.9e42.2
Anti-IL-17 13.7e20.8 8.5e24.2 4.9e7.8 CELE 13.0e30.6
RA10-6 (2 mg) 16.0e40.5 19.9e37.6 8.5e12.7 RA10-6 (4 mg) 14.8e38.0
RA10-6 (4 mg) 12.0e30.3 18.2e25.6* 6.4e13.5 RA10-6 (8 mg) 15.9e23.6
RA10-6 (8 mg) 14.8e34.8 12.1e22.3y 7.1e12.9 CELEþ RA10-6
(4 mg)
9.5e20.1z
CELEþ RA10-6
(8 mg)
8.1e17.5x
“Sham” represents the knee joints of mice that received a sham operation (a single
cutaneous incision). “CELE” represents celecoxib.
Comparisons considered to be signiﬁcant when P< 0.05.
*P¼ 0.002 vs PBS group;
yP¼ 0.001 vs PBS group;
zP¼ 0.008 vs PBS, and P¼ 0.087 vs CELE group;
xP¼ 0.001 vs PBS group, P¼ 0.016 vs CELE group, and P¼ 0.454 vs CELEþ RA10-6
(4 mg) group.
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inhibited the mRNA expression of L-1b, IL-6 and IL-8 in synovial
tissue. RA10-6 speciﬁcally suppressed the expression of IL-6 and did
not inhibit the expression of IL-1b and IL-8. Therefore, we speculate
that IL-6 production in the synovial cell ismediated by IL-17/IL-17RA
signals and IL-17-induced IL-1b and IL-8 expression may be medi-
ated by other subtypes of IL-17 receptors rather than IL-17RA.
Consistentwith this assertion is that the inhibitory effect induced by
RA10-6 is weaker than that of anti-IL-17. However, further experi-
ments will be necessary to conﬁrm our speculation.
Cartilage damage is another critical property in OA pathogenic
process. In this study, we did not ﬁnd an obvious difference in carti-
lage under microscopy between the PBS control and RA10-6 alone
treated group. Articular cartilage in the mice of both groups exhibits
pathological changes including rough joint surface, cell swelling and
disordered arrangement of chondrocytes. Nevertheless, we cannot
assert that RA10-6 had no effect on cartilage repair because precisely
corresponding experiments were not examined in this study.
Interestingly, a consensus sequence within these selected DNA
aptamers was CTAG and/or its reverse sequence GATC (present nine
times among the 20 clones). It was shown that both the CTAG and
GATC sequences within N30 region were located in the terminal
loop of the secondary structure of these aptamers. Two stem-loop
structures were observed in RA10-6, whereas the CTAG and GATC
sequences were located in one of these terminal loops. However,
such double-stem-loop structures were observed in RA10-6,
whereas other selected aptamers were single-stem-loop structures
with CTAG or GATC sequences in their terminal loops. These results
suggest that the consensus sequences of CTAG or GATC might be
critical sites for protein targeting. The possible reason that RA10-6
had the highest afﬁnity to combine with IL-17RA in vitro and
increased competitive anti-inﬂammation effects in vivo comparedTable V
Lymphocytes proliferation responds to ConA or LPS after RA10-6 treatment
Groups SI (n¼ 6) S/B weight
(103) (95% CI of
mean, n¼ 6)CD4
þ T
cells
CD8þ T
cells
B cells
PBS 8.02 6.59 6.35 5.53e6.04
RA10-6 (2 mg) 7.98 6.48 6.29 5.51e6.10
RA10-6 (4 mg) 8.04 6.60 6.44 5.49e6.12
RA10-6 (8 mg) 7.89 6.52 6.38 5.54e6.09
SI: stimulation index.
No signiﬁcant difference concerning S/B weight or SI was observed among the
groups.to other aptamers was attributed to the presence of two terminal
loops with CTAG or GATC sequences.
Current therapeutic regimens for OA include conservative
treatment and surgery as well as medical treatments, including the
use of expensive antibodies. These agents can be effective but are
limited in application. Therefore, pharmaceuticals such as NSAIDs
and COX-2 inhibitors have been widely used to alleviate synovial
inﬂammation and progressive cartilage degradation, which further
delays the time of ineluctable surgery. Therapeutic efﬁcacy strongly
correlates with initiating treatment early in the course of this
disease. In fact, both the usage of NSAIDs and COX-2 inhibitors were
complicated by their side effects, which caused many patients to
fail to continue treatment. According to our ﬁndings, RA10-6
treatment inhibited synovial thickening by potentially decreasing
IL-6 levels, and the combined application of celecoxib and RA10-6
reduced more IL-6 expression than celecoxib alone. RA10-6 also
presents a dose-dependency in combined application. This result
indicates that it is possible to reduce the dosage of celecoxib in OA
treatment and relieve associated side effects by adding RA10-6.
In conclusion, the newly developed aptamer RA10-6 inhibited
synovium inﬂammation in a murine model of OA by blocking IL-17/
IL-17RA-mediated IL-6 expression. Additional application of RA10-6
to standard celecoxib therapy for OA may reduce the effective
dosage of celecoxib and associated side effects. These ﬁndings
suggest that a DNA aptamer that speciﬁcally targets IL-17RA might
help to prevent OA. The OA model described here also provides
a new tool to screen therapeutic drugs against human joint diseases.
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